DOP2023000115A - Ácidos pirazol piperidin carboxílicos sustituidos - Google Patents

Ácidos pirazol piperidin carboxílicos sustituidos

Info

Publication number
DOP2023000115A
DOP2023000115A DO2023000115A DO2023000115A DOP2023000115A DO P2023000115 A DOP2023000115 A DO P2023000115A DO 2023000115 A DO2023000115 A DO 2023000115A DO 2023000115 A DO2023000115 A DO 2023000115A DO P2023000115 A DOP2023000115 A DO P2023000115A
Authority
DO
Dominican Republic
Prior art keywords
diseases
hfref
carboxylic acids
heart
disease
Prior art date
Application number
DO2023000115A
Other languages
English (en)
Spanish (es)
Inventor
Sandner Peter
Schmeck Carsten
Stellfeld Timo
Vakalopoulos Alexandros
Wunder Frank
Mondritzki Thomas
Ortega Hernandez Nuria
DIETZ Lisa
Boultadakis Arapinis Melissa
Candish Lisa
Collin-Kröpelin Marie-Pierre
Dieskau Andre
Mathar Ilka
Alan Webster Robert
Hudson Hofmeister Lucas
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DOP2023000115A publication Critical patent/DOP2023000115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DO2023000115A 2020-12-10 2023-06-07 Ácidos pirazol piperidin carboxílicos sustituidos DOP2023000115A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20213020 2020-12-10
PCT/EP2021/084987 WO2022122914A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (1)

Publication Number Publication Date
DOP2023000115A true DOP2023000115A (es) 2023-07-16

Family

ID=73793025

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000115A DOP2023000115A (es) 2020-12-10 2023-06-07 Ácidos pirazol piperidin carboxílicos sustituidos

Country Status (30)

Country Link
US (1) US20240051935A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259617B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552583A (cg-RX-API-DMAC7.html)
KR (1) KR20230118144A (cg-RX-API-DMAC7.html)
CN (1) CN116710439B (cg-RX-API-DMAC7.html)
AR (1) AR124297A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021393988A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204495A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001632A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007335A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230242A (cg-RX-API-DMAC7.html)
DK (1) DK4259617T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000115A (cg-RX-API-DMAC7.html)
EC (1) ECSP23040828A (cg-RX-API-DMAC7.html)
ES (1) ES2997117T3 (cg-RX-API-DMAC7.html)
FI (1) FI4259617T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247649B (cg-RX-API-DMAC7.html)
HR (1) HRP20241543T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069255T2 (cg-RX-API-DMAC7.html)
IL (1) IL303296A (cg-RX-API-DMAC7.html)
JO (1) JOP20230132A1 (cg-RX-API-DMAC7.html)
LT (1) LT4259617T (cg-RX-API-DMAC7.html)
MX (1) MX2023006903A (cg-RX-API-DMAC7.html)
PE (1) PE20231501A1 (cg-RX-API-DMAC7.html)
PL (1) PL4259617T3 (cg-RX-API-DMAC7.html)
PT (1) PT4259617T (cg-RX-API-DMAC7.html)
RS (1) RS66294B1 (cg-RX-API-DMAC7.html)
SA (1) SA523441083B1 (cg-RX-API-DMAC7.html)
SI (1) SI4259617T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022122914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CN119300815A (zh) 2022-06-09 2025-01-10 拜耳公司 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂
JP2026504406A (ja) * 2023-01-31 2026-02-05 インビボサイエンシーズ インコーポレイテッド 駆出率保持型心不全(HFpEF)の治療に関するシステムおよび方法
AU2024348074A1 (en) * 2023-09-27 2026-04-30 Haisco Pharmaceutical Group Co., Ltd. Pyrazole carboxylic acid derivative and use thereof in medicine
TW202535380A (zh) * 2024-01-30 2025-09-16 大陸商海思科醫藥集團股份有限公司 吡唑羧酸衍生物及其在醫藥上的應用
WO2026145681A1 (zh) * 2025-01-03 2026-07-09 上海齐鲁制药研究中心有限公司 杂环羧酸类衍生物、其制备方法及其在医药上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN101939053A (zh) * 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
ES2635340T3 (es) 2010-02-27 2017-10-03 Bayer Intellectual Property Gmbh Ariltriazolonas ligadas a bis-arilo y su uso
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
MX338887B (es) * 2012-09-07 2016-05-04 Boehringer Ingelheim Int Alcoxipirazoles como activadores de guanilato ciclasa soluble.
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
US20170313665A1 (en) 2014-11-03 2017-11-02 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CA3204595A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
WO2022122917A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases

Also Published As

Publication number Publication date
US20240051935A1 (en) 2024-02-15
IL303296A (en) 2023-07-01
AU2021393988A9 (en) 2024-09-19
SA523441083B1 (ar) 2025-06-12
CN116710439A (zh) 2023-09-05
CO2023007335A2 (es) 2023-06-09
ECSP23040828A (es) 2023-07-31
AR124297A1 (es) 2023-03-15
FI4259617T3 (fi) 2024-11-27
JP2023552583A (ja) 2023-12-18
LT4259617T (lt) 2024-12-10
EP4259617A1 (en) 2023-10-18
CA3204495A1 (en) 2022-06-16
GEAP202316287A (en) 2023-09-11
CL2023001632A1 (es) 2023-11-10
HRP20241543T1 (hr) 2025-01-03
ES2997117T3 (en) 2025-02-14
GEP20247649B (en) 2024-07-25
MX2023006903A (es) 2023-06-26
CN116710439B (zh) 2026-05-26
RS66294B1 (sr) 2025-01-31
KR20230118144A (ko) 2023-08-10
EP4259617B1 (en) 2024-10-23
TW202237589A (zh) 2022-10-01
PT4259617T (pt) 2024-12-05
WO2022122914A1 (en) 2022-06-16
SI4259617T1 (sl) 2025-02-28
PE20231501A1 (es) 2023-09-26
JOP20230132A1 (ar) 2023-06-08
PL4259617T3 (pl) 2025-03-17
HUE069255T2 (hu) 2025-02-28
DK4259617T3 (da) 2024-12-09
CR20230242A (es) 2023-07-19
AU2021393988A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
CO2023007335A2 (es) Ácidos pirazol piperidin carboxílicos sustituidos
DOP2023000114A (es) Ácidos pirazolo piperidin carboxílicos sustituidos
Jia et al. Arterial stiffness: a nexus between cardiac and renal disease
MX2010000927A (es) Uso de analogos y derivados de la vitamina k para el tratamiento de transtornos y condiciones de enfermedad en humanos.
Xiao et al. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects
AR061996A1 (es) Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular
EA201171361A1 (ru) Ингибиторы внешнего медуллярного калиевого канала почек
NZ715983A (en) Vasoprotective and cardioprotective antidiabetic therapy
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
BR112022003745A2 (pt) Proteínas de fusão terapêuticas
EP4488371A3 (en) Compounds and methods for modulating angiotensinogen expression
Milio et al. Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs
WO2008096816A1 (ja) 血管新生誘導剤及びそれに用いられるポリペプチド
PE20191465A1 (es) Composicion farmaceutica que comprende acido 2,5-dihidroxibencenosulfonico o una de sus sales farmaceuticamente aceptables en forma de unidades individualizadas de suministro y procedimiento de fabricacion correspondiente
WO2011132161A3 (en) Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
BR112014005518A2 (pt) 2-(cromano-6-ilóxi)-tiazóis substituídos e a utilização dos mesmos como produtos farmacêuticos
BR0315458A (pt) Utilização de tenatoprazol
Ali Hypertensive vascular disease
CL2022002838A1 (es) Derivado de arilo o heteroarilo
Banerjee et al. Comparison of Echocardiographic Patterns between Mild to Moderate and Severe CKD with type 4 Cardio renal Syndrome Patients
Otaki et al. Plasma thioredoxin-1 level is associated with renal tubular damage and predicts poor prognosis in patients with chronic heart failure
MARKER THE TAMILNADU Dr. MGR MEDICAL UNIVERSITY CHENNAI-600 032
TH102589B (th) อนุพันธ์กรดไซโคลเพนเทนคาร์บอกซิลิกที่เชื่อมต่อกันซึ่งถูกแทนที่ด้วยเอซิลอะมิโน และการใช้สารดังกล่าวเป็นสารทางเภสัชกรรม
WO2018051294A3 (en) Non—saponifiable compounds of natural lipids for use in the treatment of cardiac pathologies
TH137791A (th) อนุพันธ์กรดไซโคลเพนเทนคาร์บอกซิลิกที่เชื่อมต่อกันซึ่งถูกแทนที่ด้วยเอซิลอะมิโน และการใช้สารดังกล่าวเป็นสารทางเภสัชกรรม